<code id='5D0AADC84F'></code><style id='5D0AADC84F'></style>
    • <acronym id='5D0AADC84F'></acronym>
      <center id='5D0AADC84F'><center id='5D0AADC84F'><tfoot id='5D0AADC84F'></tfoot></center><abbr id='5D0AADC84F'><dir id='5D0AADC84F'><tfoot id='5D0AADC84F'></tfoot><noframes id='5D0AADC84F'>

    • <optgroup id='5D0AADC84F'><strike id='5D0AADC84F'><sup id='5D0AADC84F'></sup></strike><code id='5D0AADC84F'></code></optgroup>
        1. <b id='5D0AADC84F'><label id='5D0AADC84F'><select id='5D0AADC84F'><dt id='5D0AADC84F'><span id='5D0AADC84F'></span></dt></select></label></b><u id='5D0AADC84F'></u>
          <i id='5D0AADC84F'><strike id='5D0AADC84F'><tt id='5D0AADC84F'><pre id='5D0AADC84F'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:89998
          Stain of a biopsy specimen of a rhabdoid tumor -- health coverage from STAT
          Stain of a biopsy specimen of a rhabdoid tumor. Wikimedia Commons

          Most targeted cancer drugs work like tranquilizer darts, snaring an overzealous gene that has spurred the cell into murderously rapid growth.

          But many tumors don’t have a hyperactive gene. Like the mayhem in “Cat in the Hat,” they are enabled by parental absence. They grow because the genes that are meant to provide discipline, guiding the activity of other genes or self-destructing a cell whose DNA is too damaged, are broken or missing.

          advertisement

          These tumors have bedeviled researchers for decades. Restoring or fixing a protein is far harder than breaking it. And that’s bad news for humanity: Cancer is far more likely to be caused by such “tumor-suppressor” genes than by one gene run amok. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion
          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

          YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Gilead might be held responsible for not developing a drug

          JustinSullivan/GettyImagesTheassaultonthedevelopmentofnewlifesavingtherapiescontinuesapace.Recently,